EBV TCR-T cells

N/A

Report date: 2025/03/18 20:00:05

Base Information

Drug NameEBV TCR-T cells
Drug Alias Nameanti-EBV TCR T-cell therapy (Guangzhou Bioresette Biomedical Technology/The Affiliated Hospital of Xuzhou Medical University)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionImmunostimulantsT lymphocytes stimulants
TargetsUpdating
Therapy Area/IndicationsNasopharyngeal CarcinomaLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaClinical
Originator CompaniesGuangzhou Bioresette Biomedical Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGuangzhou Bioresette Biomedical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsNasopharyngeal CarcinomaLymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A